Phase II Study of Raloxifene in Recurrent Endometrial Cancer
OBJECTIVES: I. Determine response rate and time to disease progression in patients with
recurrent endometrial cancer treated with raloxifene. II. Determine overall survival in
these patients treated with this regimen. III. Determine the toxicity of raloxifene in this
patient population.
OUTLINE: Patients receive oral raloxifene daily. Treatment continues indefinitely in the
absence of disease progression or unacceptable toxicity. Patients are followed every 3
months.
PROJECTED ACCRUAL: A total of 13-50 patients will be accrued for this study within 2.5
years.
Interventional
Primary Purpose: Treatment
Phillip Y. Roland, MD
Study Chair
Florida Gynecologic Oncology - Fort Myers
United States: Federal Government
NU 98G1
NCT00004915
November 1998
February 2000
Name | Location |
---|---|
Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago, Illinois 60611 |